Novartis: positive results in phase III study

(CercleFinance.com) - Novartis reports that Jakavi (ruxolitinib) has met the primary endpoint of the Phase III acute graft-versus-host disease study.


The results of the REACH2 trial confirm that Jakavi significantly improves the overall response rate at 28 days compared to the best treatment available in the treatment of acute graft-versus-host disease (GvHD).

GvHD is a serious and frequent complication of stem cell transplants with a one-year mortality rate as high as 60%-80% in its acute form.

Novartis plans to present the full results of REACH2 at a forthcoming medical conference and to begin discussions with the US regulatory authorities in 2020.


Copyright (c) 2019 CercleFinance.com. All rights reserved.